Dal CantoECerielloARydénL, et alDiabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol2019;
26 (2_Suppl): 25–32.
2.
RydénLFerranniniGMellbinL.Risk factor reduction in type 2 diabetes demands a multifactorial approach. Eur J Prev Cardiol2019;
26 (2_Suppl): 81–89.
3.
PrattichizzoFLa SalaLRydénL, et al.
Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Eur J Prev Cardiol2019;
26 (2_Suppl): 73–80.
4.
PulipatiVPRaviVPulipatiP. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Eur J Prev Cardiol 2020; 27: 1922–1930.
5.
Di BenedettoLMichelsGLubenR, et al.
Individual and combined impact of lifestyle factors on atrial fibrillation in apparently healthy men and women: the EPIC-Norfolk prospective population study. Eur J Prev Cardiol2018;
25: 1374–1383.
6.
LeeYChaSJParkJH, et al.
Association between insulin resistance and risk of atrial fibrillation in non-diabetics. Eur J Prev Cardiol 2020; 27: 1934–1941.
7.
CortesiPAFornariCMadottoF, et al.
Trends in cardiovascular diseases burden and vascular risk factors in Italy: the Global Burden of Disease Study19902017. Eur J Prev Cardiol. Epub ahead of print 24 August 2020. DOI: 10.1177/2047487320949414
8.
ByambasukhOEisengaMFGansevoortRT, et al.
Body fat estimates from bioelectrical impedance equations in cardiovascular risk assessment: the PREVEND cohort study. Eur J Prev Cardiol2019;
26: 905–916.
9.
MohammadiHOhmJDiscacciatiA, et al.
Abdominal obesity and the risk of recurrent atherosclerotic cardiovascular disease after myocardial infarction. Eur J Prev Cardiol 2020; 27: 1944–1952.
10.
Garcia-RubiraJCCano-GarciaFJBullonB, et al.
Body fat and metabolic age as indicators of inflammation and cardiovascular risk. Eur J Prev Cardiol2018;
25: 233–234.
11.
SchroverIMvan der GraafYSpieringW, et al.;
SMART study group. The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease. Eur J Prev Cardiol2018;
25: 1548–1557.
12.
Alvarez-AlvarezIde RojasJPFernandez-MonteroA, et al.
Strong inverse associations of Mediterranean diet, physical activity and their combination with cardiovascular disease: the Seguimiento Universidad de Navarra (SUN) cohort. Eur J Prev Cardiol2018;
25: 1186–1197.
13.
YiSYSteffenLMTerryJG, et al.
Added sugar intake is associated with pericardial adipose tissue volume. Eur J Prev Cardiol 2020; 27: 2016–2023.
14.
KwokCSGulatiMMichos EDet al.
Dietary components and risk of cardiovascular disease and all-cause mortality: a review of evidence from meta-analyses. Eur J Prev Cardiol2019;
26: 1415–1429. DOI: 10.1177/2047487319843667
15.
WangXLiuFLiJ, et al.
Tea consumption and the risk of atherosclerotic cardiovascular disease and all-cause mortality: the China-PAR project. Eur J Prev Cardiol 2020; 27: 1956–1963.
16.
TverdalASelmerRCohenJM, et al.
Coffee consumption and mortality from cardiovascular diseases and total mortality: does the brewing method matter?Eur J Prev Cardiol 2020; 27: 1986–1993.
17.
BaumeisterSEFingerJDGläserS, et al.
Alcohol consumption and cardiorespiratory fitness in five population-based studies. Eur J Prev Cardiol2018;
25: 164–172.
18.
Spiegelman D, Lovato LC, Khudyakov P, et al.
The Moderate Alcohol and Cardiovascular Health Trial (MACH15): Design and methods for a randomized trial of moderate alcohol consumption and cardiometabolic risk. Eur J Prev Cardiol 2020; 27: 1967–1982.
19.
ScherrerJFSalasJLustmanP, et al.
Combined effect of posttraumatic stress disorder and prescription opioid use on risk of cardiovascular disease. Eur J Prev Cardiol2020;
27: 1412–1422. DOI: 10.1177/204748731985071
20.
MasoudkabirFYavariNPashangM, et al.
Effect of persistent opium consumption after surgery on the long-term outcomes of surgical revascularisation. Eur J Prev Cardiol 2020; 27: 1996–2003.
